Is Genmab A/S (GMAB) Overvalued?
We dive into why Genmab A/S (GMAB) could be considered overvalued on 2026-07-21, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Commentary & Analysis
Why Genmab A/S’s (GMAB) Stock Is Up 6.46%
As of Tuesday, June 30, Genmab A/S’s GMAB share price has surged by 6.46%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genmab A/S’s (GMAB) Stock Is Down 5.60%
As of Tuesday, June 02, Genmab A/S’s GMAB share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Genmab A/S’s (GMAB) Stock Is Up 5.18%
As of Wednesday, May 20, Genmab A/S’s GMAB share price has surged by 5.18%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genmab A/S’s (GMAB) Stock Is Down 7.45%
As of Tuesday, March 03, Genmab A/S’s GMAB share price has dipped by 7.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $17,340.3 | $251.9 | 84% |
|
| Shares Out (Mil) | 63.9 | 50.8 | 54% |
|
| Institutional Ownership | 98.0% | 92.0% | 77% |
|
| Float (Mil) | 60.7 | 40.5 | 52% |
|
| Beta | 0.69 | 0.95 | 40% |
|
| Avg Daily Volume (000s) | 1,598 | 447 | 78% |
|
| Price Change (52-week) |
26.7% | 54.2% | 67% |
|
| Growth | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.5% | 14.0% | 78% |
|
| Net Income (5yr) | 4.3% | (9.8%) | 46% |
|
| EPS (5yr) | 5.3% | 16.3% | 38 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (37.6%) | (15.6%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | $0.346 | $1.320 | $1.880 | |
| Month Ago EPS | $3.386 | $11.449 | $16.296 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | $3.586 | $11.514 | $16.576 | |
| Year/Year Chg | (58.3%) | (91.4%) | (80.5%) | |
| Financials | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,901 | $39 | 71% |
|
| Net Income (TTM) (Mil) | $821 | ($43) | 84% |
|
| EPS (TTM) | $13.243 | ($1.600) | 96% |
|
| Operating Cash Flow (TTM) (Mil) | $902 | ($30) | 79% |
|
| Net Cash Flow (TTM) (Mil) | ($324) | $3 | 8% |
|
| Long-Term Debt (Q1) (Mil) | $5,058 | $5 | 86% |
|
| Enterprise Value (Q1) (Mil) | $19,702 | $182 | 83% |
|
| Valuation | GMAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.31 | 2.60 | 5% |
|
| P/E | 2.2 | 18.6 | 2% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.4 | 0.9 | 19% |
|
| Ratios | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.3% | 63.8% | 95% |
|
| Net Margin | 21.0% | (64.7%) | 80% |
|
| ROA | 8.7% | (49.7%) | 85% |
|
| ROE | 15.2% | (55.4%) | 72% |
|
| Liabilities to Assets | 54.1% | 30.3% | 47% |
|
| F-Score | 4 | 3 | 34% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Fisher (Philip) Screen
Factors: Value, Growth
A perspective on the evolution of the investment philosophy of a successful money manager who learned from his mistakes.
| Performance Since Inception: | 4.6% |
| +/- S&P 500: | -2.9 |
Passing Stocks
See All 2 Stocks (as of 7/30/2026)
GURU STRATEGY
Neff Screen
Factors: Value, Growth
An approach using a stringent contrarian viewpoint—finding undervalued, out-of-favor stocks in the bargain basement that have an optimistic future.
| Performance Since Inception: | 14.4% |
| +/- S&P 500: | +6.9 |
